{"nctId":"NCT02197702","briefTitle":"Vitamin D in Preschoolers With Viral-induced Asthma","startDateStruct":{"date":"2014-09"},"conditions":["Asthma"],"count":47,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: placebo"]},{"label":"Vitamin D","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: vitamin D"]}],"interventions":[{"name":"vitamin D","otherNames":["cholecalciferol"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age 1-5 years\n* physician-diagnosed asthma as per the Global Initiative for Asthma (GINA) guidelines\n* URTIs as the main asthma trigger (parental report)\n* ≥4 URTIs in the past 12 months (parental report)\n* ≥1 asthma exacerbation requiring rescue oral corticosteroids (OCS) in the past 6 months or ≥2 in the past 12 months\n\nExclusion Criteria:\n\n* intake or intention to use more than 400 IU/day of vitamin D supplement\n* extreme prematurity (\\<28 weeks gestation)\n* infants \\<12 months of age\n* no vitamin D supplementation when breast-fed\n* recent (\\<1 year) immigrants from a region at high risk of rickets\n* children with vitamin D restrictive diets e.g. vegans\n* other chronic respiratory disease (broncho-pulmonary dysplasia; cystic fibrosis)\n* condition(s) that alter calcium or vitamin D metabolism/absorption (hypo/hyperparathyroidism, kidney/liver disease, inflammatory bowel disease)\n* medications that interfere with vitamin D metabolism (anti-epileptics, diuretics, antacids, anti-fungal drug)\n* vitamin D supplementation \\>1000 IU/ day in last 3 months\n* anticipated difficult follow-up (unable to attend clinic visits; plan to leave the province).","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Serum 25OHD","description":"Group difference in the adjusted change from baseline 25OHD over 7 months","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Total 25OHD ≥75 Nmol/L","description":"Group difference in the number of participants with total 25OHD ≥75 nmol/L","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Emergency Department Visit for an Asthma Flare-up","description":"Group difference in the number of emergency department visits for asthma per child","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.04","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hypercalciuria","description":"Group difference in the number of participants with ≥1 occurrence of hypercalciuria (urinary calcium: creatinine greater than 1.25mmol/mmol for children aged 1-2yrs or greater than 1mmol/mmol for those aged 2-5yrs)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Elevated Serum 25-hydroxyvitamin D (25OHD)","description":"Number of Participants with ≥1 occurrence of elevated serum 25OHD (greater than 225 nmol/L)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Perturbation of the Calcium Homeostasis","description":"Number of participants with ≥1 occurrence of a clinically significant perturbation of the calcium homeostasis (serum Ca, Ph, Alkaline phosphatase), defined as outside normal laboratory values","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of URTIs (Verbal Report)","description":"Adjusted Incidence proportion of URTIs (the event rate per child occurring during the 7-month follow up period)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.12","spread":null},{"groupId":"OG001","value":"4.48","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Viral Upper Respiratory Tract Infections (URTI)","description":"Group difference in the number of reported viral upper respiratory tract infections reported in the ADYC diary.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.24","spread":null},{"groupId":"OG001","value":"3.63","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Rescue β2-agonist Use During an Asthma Flare-up (Standardized Over 7 Days)","description":"Group difference in the cumulative daily use of rescue β2-agonist use, standardized over 1 week, as documented by parents on the 'Asthma Flare-up Diary for Young CHildren' (ADYCs) during a URTI or an asthma exacerbation. A cumulative number of inhalations documented in ADYC were divided by the number of days of asthma exacerbation and multiplied by 7 days. Albuterol doses received during acute care visits and hospital admissions were not considered.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"40.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Severity of Asthma Symptoms During an Asthma Flare-up (Cumulative Daily Score Standardized Over 7 Days)","description":"Group difference in the severity on the asthma symptoms documented as the sum of daily score on the 'Asthma FLare-up DIary for Young Children' questionnaire where best =1, worst = 7 on each day during asthma flare-up. Since the flare-up typically lasts several days, the cumulative daily score, standarized over 7 days (total possible scale range: 7-49), may increase due to severity or due to the duration of the event. Lower scores indicate lowest severity, higher score indicate longer or higher severity of symptoms.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Duration of Asthma Symptoms During a Flare-up (by Diary)","description":"Group difference in the duration of asthma symptoms documented on the 'Asthma FLare-up DIary for Young Children' questionnaire","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Asthma Exacerbations/Child","description":"The number of asthma exacerbations requiring rescue oral corticosteroids per child","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":null},{"groupId":"OG001","value":"0.96","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Impact of Exacerbations on Caregivers' Functional Status","description":"Group difference in the caregivers' functional status measured on the 'Effect of a child's asthma flare-up on parents' (ECAP) questionnaire (best =7, worst = 1)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Caregivers' Workday Lost (in Days Per Flare-up)","description":"Mean group difference in the caregivers' number of workdays lost per exacerbation, reported in number of days per flare-up","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent of Participants With at Least 1 Exacerbation Requiring Rescue Oral Corticosteroids","description":"The percentage of participants with ≥1 reported asthma exacerbations requiring rescue oral corticosteroids","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Duration of Asthma Symptoms During a Flare-up (Verbal Report)","description":"Group difference in the duration of asthma symptoms by verbal report.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":24},"commonTop":["infections and infestations (SOC)","General (SOC)","Investigations (SOC)","Respiratory (SOC)","Gastrointestinal disorders (SOC)"]}}}